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Background: Gastro esophageal reflux (GER) is common in cystic fibrosis (CF) and may contribute to lung disease.
Approximately 50% of patients with cystic fibrosis are being treated with proton pump inhibitors (PPIs).
Methods: In a randomized controlled study in adults, we compared treatment with esomeprazole 40 mg twice
daily versus placebo in patients with CF and frequent respiratory exacerbations over a thirty-six week treatment
period to determine effect on time to first exacerbation and other health related outcomes.
Results: 17 patients without symptoms of GER were randomized and 15 completed the study. 13 subjects
underwent 24 hour ambulatory pH probe monitoring; 62% had pH probe evidence of GER. Forty one percent
of subjects had a pulmonary exacerbation during the study. There was no significant difference in time to first
pulmonary exacerbation (log rank test p = 0.3169). Five of nine subjects in the esomeprazole group compared with
2 of eight subjects in the placebo group experienced exacerbations (esomeprazole vs. placebo: odds ratio = 3.455,
95% CI = (0.337, 54.294), Fisher’s exact test: p = 0.334). There was no change in Forced Expiratory Volume in one
second, Gastroesophageal Symptom Assessment Score or CF Quality of Life score between the two treatment
groups.
Conclusions: There was a trend to earlier exacerbation and more frequent exacerbations in subjects randomized
to esomeprazole compared with placebo. The effect of proton pump inhibitors on pulmonary exacerbations in CF
warrants further investigation.
Clinical trials registration: Clinicaltrials.gov, NCT01983774Background
Gastroesophageal reflux (GER), both symptomatic and
silent, is frequent in patients with cystic fibrosis (CF),
and is often regarded as playing a role in the pathogenesis
of CF related lung disease [1-4]. The overall prevalence of
GER in CF is not well established, but is reported to be as
high as 80% when diagnosed by esophageal pH-probe
monitor in CF adults [3,5]. One study reported that 91%
of patients with CF awaiting lung transplant had evidence
of GER by pH probe monitoring [6]. Symptoms of lung
disease in CF may overlap with pulmonary symptoms of
gastroesophageal reflux, making it difficult to distinguish
between the two conditions and often leading to treat-
ment of both conditions. In 2010 in the US, 48% of adults* Correspondence: ead3@columbia.edu
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reproduction in any medium, provided the orand 51% of children with CF were being treated with pro-
ton pump inhibitors [7].
Several studies have suggested that patients with CF
who have GER have more severe lung disease with lower
pulmonary function and increased numbers of respira-
tory exacerbations [2,8]. In a prospective study, Button
etal demonstrated that children with CF receiving modi-
fied chest physiotherapy with avoidance of head in the
tilt down position not only had reduced episodes of GER
as measured by ambulatory pH probe, but also had re-
duced need for antibiotics, reduced number of hospital
days and improved lung function over a five year period
[9]. The European Epidemiologic CF Registry reported
that patients with CF and GER had lower pulmonary
function than those without GER [8]. A recently con-
ducted retrospective study of Nissen fundoplication in
patients with CF and GER showed a significant declineal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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expiratory volume in one second (FEV1) during the two
years following surgery compared to the two years pre-
ceding surgery [10]. Despite considerable evidence that
GER is common in CF and may be associated with more
severe lung disease, the effect of acid suppressor therapy
on improving lung function and reducing pulmonary ex-
acerbations has not been prospectively studied.
Proton pump inhibitors (PPIs) suppress the production
of gastric acid and several studies have tested their effect-
iveness in improving pulmonary outcomes in chronic re-
spiratory diseases. Studies of PPI therapy in asthma have
inconsistently demonstrated beneficial effects [11,12], and
retrospective studies in idiopathic pulmonary fibrosis sug-
gest stabilization of lung function and improved survival
with acid suppression [13,14] , Among individuals with
CF , PPIs are likely initiated for a variety of reasons includ-
ing improved efficacy of pancreatic enzymes in a higher
pH environment, as well as treatment of cough or other
respiratory or gastrointestinal complaints thought to be
possibly caused by GER. Use of these agents however, may
be associated with risk [15,16]. Use of PPIs in both hospi-
talized and ambulatory patients has been shown to be as-
sociated with an increased risk of pneumonia [15-18].
Furthermore, PPIs have been implicated in accelerated
bone loss [19,20]. We compared treatment with esome-
prazole versus placebo in a pilot study of patients with CF
and frequent respiratory exacerbations to determine
whether suppression of gastric acid leads to longer time to
first pulmonary exacerbation and improvements in other
health related outcomes.
Methods
We conducted a randomized, placebo-controlled double
blind trial of esomeprazole in adult patients with cystic
fibrosis. Adults with cystic fibrosis were enrolled from
the clinical practices of two adult cystic fibrosis pro-
grams in New York City. Inclusion criteria were age of
18 years or older and two to four respiratory exacerba-
tions per year requiring oral and/or intravenous antibi-
otics for each of the two years prior to study entry. At
the time of enrollment, subjects had to have been on a
stable maintenance medical regimen for at least six
weeks. Participants were excluded if they were being
treated with PPIs, were receiving enteral feeds, had
smoked cigarettes within the previous six months, had
previous anti-reflux surgery or clinical indications for
acid-suppressor treatment (i.e. two or more episodes per
week of heartburn requiring antacids). Participants were
also excluded if they were being treated with medica-
tions that interact with proton pump inhibitors (azoles,
iron, anti-coagulants), were pregnant or had a pulmonary
exacerbation requiring antibiotics within the previous two
weeks. All participants provided written informed consentstatements that had been approved by the Columbia
University Institutional Review Board (IRB AAAC8262)
and the Beth Israel Medical Center Institutional Review
Board (IRB 074-10).
After the screening visit, those subjects who met eligi-
bility criteria were enrolled in a 2 week run-in period
during which time they underwent 24-hour ambulatory
pH probe monitoring. Calibrated pH probes were placed
in the distal esophagus using esophageal manometry,
5 cm above the lower esophageal sphincter. Criteria for
an acceptable study included total recording time of at
least 16 hours, with at least one meal and 2 hours of re-
cumbency. A study was considered positive for distal
GER if the distal pH was less than 4 more than 5.8%
total time, or more than 8.2% of upright time, or more
than 3.5% of supine time [21,22]. Meal times were ex-
cluded in the analysis to avoid false-positive data. A single
gastroenterologist at each of the two centers reviewed
studies; study subjects and study investigators were
blinded to the results.
Fourteen days after screening, subjects were randomly
assigned in a 1:1 ratio to receive either esomeprazole
40 mg twice daily or matching placebo, regardless of pH
probe results. The Columbia University Research Pharmacy
prepared study medication. At the randomization visit,
baseline spirometry, CF related quality of Life (CFQ-R
QOL) [23] and Gastroesophageal Symptom Assessment
Score (GSAS) measuring number and severity of reflux
symptoms [24] were collected. Randomization was strati-
fied based on study center and FEV1 decile. Primary
outcome measure was time to first pulmonary exacer-
bation. Secondary outcomes included exacerbation rate,
change in FEV1, forced vital capacity (FVC), CFQ-R
QOL score and GSAS score. After randomization, partici-
pants returned to the clinic every six weeks for 36 weeks.
Outcome measures were re-assessed at 12, 24 and
36 weeks after randomization. Subjects were instructed to
notify the study site if they had signs or symptoms of a
pulmonary exacerbation or if they were treated for a
pulmonary exacerbation. Pulmonary exacerbation was
defined as initiation of treatment with intravenous or oral
antibiotics for 7 or more days based on respiratory symp-
toms at the discretion of the treating physician [24,25].
Additionally, at each visit, subjects answered questions
from a checklist to ensure that all exacerbation events
were captured.
Statistical analysis
Summary statistics were calculated for sample characte-
ristics of each treatment group. Fisher’s exact method
and Wilcoxon rank sum test was used to detect treat-
ment group differences in baseline binary and quantita-
tive variables respectively. Kaplan-Meier product limit
method was used to estimate cumulative probability
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group and log rank test was used to detect group diffe-
rence in the curve. Rate of exacerbation defined as num-
ber of exacerbations per person year was calculated by
treatment group and negative binomial model was used
to examine treatment group differences. Linear model
with repeated measures were used to examine treatment
group difference in FEV1, FVC, CFQ-R and GSAS over time.
For participants who were withdrawn after randomization,
longitudinal analyses compared each value at the start of the
treatment period to the last observed value carried forward
for each variable examined.
Results
Twenty one subjects were screened; two subjects with-
drew consent before randomization, one subject was in-
eligible based on daily symptoms of GER (an indication
for acid suppressor therapy) and one subject was ineli-
gible due to frequency of exacerbations being above the
threshold for enrollment. Of the 17 subjects who were
randomized, four were unable to tolerate insertion of the
pH probe but remained in the study. Fifteen subjects
completed the study; all randomized subjects are in-
cluded in the analysis (Figure 1). There were no signifi-
cant differences between subjects randomized to placebo
and those randomized to esomeprazole, though the pla-
cebo group tended toward lower lung function, moreAssessed for e
Analysed  (n=9)
Lost to follow-up (moved) (n=1)
Allocated to esomeprazole (n=9)
Received allocated intervention (n=9)
Allocat
Anal
Follow
Random
Figure 1 Flow diagram for screened and enrolled subjects.frequent exacerbations and lower body mass index
(BMI) (Table 1). Of the subjects who underwent 24 hour
pH probe monitoring, five of eight subjects (62.5%) in the
esomeprazole group and three of five subjects (60%) in the
placebo group had probe evidence of GER. There were no
significant differences in baseline characteristics be-
tween subjects with and without evidence of distal
GER (Table 2).
Forty one percent of 17 subjects had a pulmonary ex-
acerbation during the study. Five of nine subjects in the
esomeprazole group compared with 2 of 8 subjects in
the placebo group experienced exacerbations (esomepra-
zole vs. placebo: odds ratio = 3.455, 95% CI = (0.337,
54.294). There was no significant difference in time to
first pulmonary exacerbation between the esomeprazole
and placebo groups (log rank test p = 0.3169) (Figure 2).
Similarly, there was no significant difference between
groups in exacerbation rate during the study period
(2.04 exacerbations per person year in esomeprazole
group 95% CI (1.33, 4.14) compared with 0.59 exacerba-
tions per person year in placebo group (95% CI (0.19,
1.82), p = 0.07. There was no significant change in FEV1
percent predicted or FVC percent predicted in either
group over the study period, p = 0.23 and 0.58, respect-
ively, and there was no difference between groups in
change in FEV1 or FVC percent predicted from baseline
to end of study (Figure 3). GSAS and CFQ-R score didligibility (n=21 )
Excluded  (n=4 )
Not meeting inclusion criteria (n=2 )
Declined to participate (n=2 )
Discontinued intervention (underwent lung 
transplantation) (n= 1)
Allocated to placebo (n= 8)
Received allocated intervention (n=8)
Analysed  (n=8)
ion
ysis
-Up
ized (n=17)
Table 1 Baseline characteristics of subjects by treatment
assignment
Esomeprazole
(n = 9)
Placebo
(n = 8)
p value
Reflux present on pH probe 5/8 (62%) 3/5 (60%) 0.42
Male (%) 67 75 0.38
Pseudomonas present (%) 89 62
MRSA present(%) 0 25
Mean + SD Mean + SD
Age (years) 35.72 + 9.6 32.81 + 5.84 0.41
BMI 24.25 + 4.72 21.84 + 3.02 0.21
# exacerbations past 2 years 4 + 0 (0) 5.5 + 1.4 (SD)
FEV1 (%) 58 + 19 46 + 21 0.14
FVC (%) 74 + 20 71 + 16 0.88
FEV1/FVC 0.63 + 0.10 0.56 + 0.15 0.26
GSAS distress score 0.99 + 0.61 0.88 + 1.03 0.28
CFR-QOL score 72.28 + 10.32 77.85 + 18.86 0.34
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and 0.32, respectively) and there was no difference in
change in scores between the two treatment groups.
Discussion
Individuals with CF have many predisposing factors to
the development of GER including airway hyperinflation,
frequent cough, hyperalimentation, delayed gastric empty-
ing, high fat diet and positional changes related to per-
formance of chest physiotherapy [25]. Twenty-four hour
esophageal pH monitoring has the highest sensitivity and
specificity for the detection of GER and is widely regarded
as the gold standard for quantifying esophageal pH. We
demonstrate that the majority of patients with cystic fibro-
sis in our cohort have evidence of distal esophageal reflux
as measured by esophageal pH monitoring despite ab-
sence of symptoms. In the small prospective study re-
ported here, suppression of gastric acid with esomeprazole
did not lead to significant improvement in pulmonary out-
comes. An unanticipated finding of this study was a trend
to earlier exacerbation and more frequent exacerbationsTable 2 Comparison of subjects with and without
gastroesophageal reflux as measured by 24 hour
ambulatory pH probe
+pH probe
(n = 8)
-pH probe
(n = 5)
p value
Age 33.8 (4.37) 37 (16.5) 0.59
FEV1 (%) 51 (17) 59 (20) 0.45
BMI 23.5 (2.7) 21.8 (5/2) 0.43
GSAS 0.65 (0.29) 0.59 (0.21) 0.88
+ exacerbations
previous two years
5.5 (1.4) 4 (0) 0.33in patients randomized to esomeprazole compared with
placebo.
In 2010, the Cystic Fibrosis Foundation Patient Registry
reported that 50.7% of children less < 18 years and
48.2% of adults > 18 years were being treated with pro-
ton pump inhibitors. Though studies have suggested
that treatment of GER is associated with improvement
in other lung diseases, prospective studies have not
been conducted in CF to determine whether reducing
gastric pH has a beneficial effect on pulmonary exacer-
bations or other health related outcomes. The possible
mechanisms whereby gastroesophageal reflux leads to
respiratory symptoms in CF and other chronic lung dis-
eases have not been established. Some investigators
speculate that reflux into the esophagus, particularly in
the supine position, results in intermittent aspiration of
acidic stomach contents into the airways compounding
the effects of the vicious cycle of inflammation, infec-
tion and progression of lung disease that has been well
described in CF. Mendez, et al demonstrated that even
after lung transplantation, 90% of patients with CF had
evidence of GER compared with only 54% of patients
who underwent lung transplant for other diseases. The
majority of CF patients had evidence of proximal and
distal GER [26]. Tracheal acidification has in fact been
demonstrated in adults with CF while in the supine
position [27]. It is further hypothesized that afferent re-
ceptors within the esophageal mucosa, when stimulated
by exposure to acid, trigger outputs along motor neu-
rons to the respiratory muscles and tracheobronchial
tree, resulting in cough, bronchospasm and perhaps
even increase in neutrophilic airway inflammation
[28,29]. A relationship between GER and the develop-
ment of obliterative bronchiolitis after lung transplan-
tation, with improved allograft function after Nissen
fundoplication has been reported by Davis and col-
leagues [30]. However, a large prospective study of the
effect of PPIs on asthma exacerbations did not show an
improvement in asthma outcomes [11].
PPIs address only the acid component of reflux, and
there is evidence that non-acid reflux, such as bile
salts from the small intestine, may also be lung irritants.
Tamhankar and others have demonstrated that omepra-
zole does not reduce the number of reflux episodes or
their duration, but acts to convert acid reflux to less acid
reflux [31]. Doumit et al showed that among children
with CF, 63% of reflux episodes were acid compared with
37% which were non acid [32]. In a study by Pauwels, et
al, 56% of patients with CF had bile acids in the sputum,
providing evidence for the aspiration of duodenogastric
contents [25]. Furthermore, concentration of bile acids
correlated with neutrophil elastase in sputum, degree of
lung function impairment and need for IV antibiotic
treatment.
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Figure 2 Time to first exacerbation in treatment group assigned to esomeprazole versus placebo. Log rank test p = 0.3169.
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hospital and community acquired pneumonia, as dem-
onstrated by several retrospective studies of PPI use in
both the in-patient and outpatient setting [15,16]. Indi-
viduals with CF have chronic airway infections with a
host of pathogens, notably Pseudomonas aeruginosa and
Staphylococcus aureus. Despite widespread use of PPIsWeeks
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Our randomized placebo controlled double blind study
of the effect of proton pump inhibitors on pulmonary ex-
acerbations in a group of patients with CF and a known
history of recurrent exacerbations was designed as a fea-
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strated that in a population of patients with CF and recur-
rent pulmonary exacerbations, 60% of patients have
asymptomatic acid GER. These results are consistent with
those reported by Brodzicki et al where 55% of children
with CF had GER, despite the absence of symptoms in
many of those patients [33]. There was a trend toward
shorter time to first pulmonary exacerbation and higher
exacerbation rate in patients randomized to esomeprazole
compared with placebo, despite that fact that the placebo
group had more frequent exacerbations during the two
years prior to study enrollment . Though the study en-
rolled only subjects with frequent pulmonary exacerba-
tions (between 2 and 4 per year), there was a relatively low
incidence of pulmonary exacerbations during the treat-
ment period in that only 42% of subjects experienced an
exacerbation over a thirty-six week period. This may be
related to the introduction of new therapies during the
study period, such as hypertonic saline and inhaled aztreo-
nam lysine. [34,35].
Our study hypothesized that gastric acid suppression
would prolong time to first pulmonary exacerbation,
thus adequate gastric acid suppression was an essential
component of the study design. Esomeprazole was se-
lected because of its high potency for gastric acid sup-
pression; the twice-daily dose of 40 mg has been shown
to effectively suppress gastric acid in about 95% of pa-
tients [30]. 36 weeks was chosen for study duration to
allow long enough follow up time for development of re-
spiratory exacerbation in the majority of patients. Our
study findings are limited by small sample size without
adequate power to detect significant differences between
subjects treated with esomeprazole compared with pla-
cebo. However, trends regarding frequency of exacerba-
tion and time to exacerbation were consistent in the
esomeprazole group. The fact that our results align with
reports from several retrospective studies demonstrating
an increased risk of lower respiratory tract infections in
patients taking PPIs, and that patients with cystic fibro-
sis chronically harbor bacterial pathogens and develop
recurrent pulmonary exacerbations, suggests that further
investigation into the possible effects of PPIs on pul-
monary infections in CF is warranted.
This work was previously presented in Abstract form at
the North American Cystic Fibrosis Conference 2012 [33].
Conclusion
Asymptomatic gastroesophageal reflux is present in the
majority of patients with cystic fibrosis. Risk and benefits
of acid suppressive agents in cystic fibrosis require fur-
ther study.
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